Zepbound (Tirzepatide) and Surgery: Perioperative Management
Tirzepatide (Zepbound) should be held for one week (7 days) before elective surgery to minimize aspiration risk, though this recommendation must be balanced against the metabolic consequences of discontinuation in patients with diabetes.
Key Recommendation
For patients on weekly tirzepatide, discontinue the medication one week prior to elective surgery 1. This timing is based on the drug's elimination half-life and the theoretical risk of delayed gastric emptying leading to pulmonary aspiration during anesthesia induction.
Risk-Benefit Analysis
Aspiration Risk
The evidence shows concerning signals for pulmonary aspiration risk:
- Odds ratio of 10.23 (95% CI: 2.94-35.82) for aspiration in elective surgery when GLP-1 receptor agonists are continued 1
- Hazard ratio of 1.33 (95% CI: 1.02-1.74) in endoscopy settings 1
- The European Medicines Agency's Pharmacovigilance Risk Assessment Committee has highlighted delayed gastric emptying as a likely effect 1
Metabolic Benefits Lost
However, stopping tirzepatide eliminates important perioperative advantages:
- Improved perioperative glycemic control
- Lower postoperative insulin requirements
- Reduced hypoglycemia risk
- Improved cardiovascular outcomes 1
Critical Nuances and Caveats
The Tachyphylaxis Question
There is substantial uncertainty about aspiration risk in long-term users 1. The gastric emptying effects may diminish over time (tachyphylaxis), meaning chronic users might have lower aspiration risk than the data suggest. However, given the severity of pulmonary aspiration (mortality risk), the consensus errs on the side of caution 1.
Conflicting Evidence
The 2025 multidisciplinary consensus acknowledges "conflicting data on the magnitude of these risks" 1. Some studies show much lower aspiration rates than the odds ratio above suggests. The 2026 review notes that "large cohort studies now demonstrate exceedingly low incidences of pulmonary aspiration" in real-world settings 2.
Despite this uncertainty, the most recent high-quality guideline from multiple major societies (Association of Anaesthetists, Royal College of Anaesthetists, and others) recommends the one-week hold 1.
Algorithmic Approach to Decision-Making
Step 1: Classify the Surgery
- High aspiration risk procedures (upper GI surgery, emergency surgery, difficult airway): Mandatory 7-day hold
- Standard elective procedures: 7-day hold per guideline
- Procedures not requiring general anesthesia: Consider continuing if aspiration risk is minimal
Step 2: Assess Patient Factors
For patients with diabetes:
- If A1C >8%: The metabolic risk of stopping may be significant; consider postponing surgery for optimization 3
- If cardiovascular disease present: Weigh the cardiovascular benefits of tirzepatide continuation more heavily
- If obesity surgery candidate: The one-week hold is standard practice 1
Step 3: Coordinate with Anesthesia
- Inform anesthesia team of tirzepatide use regardless of timing
- Even with 7-day hold, consider rapid sequence induction if other risk factors present
- Point-of-care gastric ultrasound may be considered to assess gastric contents 1
Perioperative Glucose Management
When tirzepatide is held:
For patients with diabetes:
- Target perioperative glucose 100-180 mg/dL 3
- Transition to basal insulin at 75-80% of calculated dose 3
- Use correctional insulin protocols
- Do not use CGM alone for intraoperative monitoring 3
For weight-loss-only patients (no diabetes):
- Monitor glucose perioperatively but insulin typically not needed
- Resume tirzepatide postoperatively once oral intake established
Other Medications to Hold
Coordinate discontinuation of other diabetes medications 3:
- SGLT2 inhibitors: Stop 3-4 days before surgery (ketoacidosis risk)
- Metformin: Hold day of surgery
- Other oral agents: Hold morning of surgery
Common Pitfalls to Avoid
- Don't assume tachyphylaxis protects long-term users – the evidence is insufficient to modify the recommendation
- Don't forget to restart postoperatively – patients benefit from resumption once tolerating oral intake
- Don't use the daily GLP-1 RA timing (hold day before) for weekly tirzepatide – it requires the full week
- Don't ignore the A1C – if >8%, consider delaying elective surgery for optimization 3
Postoperative Resumption
- Resume tirzepatide when patient tolerates regular oral intake
- No specific washout period needed postoperatively
- Continue glucose monitoring during transition period
The 2025 multidisciplinary consensus represents the highest quality, most recent guidance and should be followed despite emerging real-world data suggesting lower aspiration rates than initially feared 1. The recommendation prioritizes patient safety (avoiding aspiration mortality) over metabolic optimization in the perioperative window.